Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dexamethasone pulse therapy in pemphigus.

G G Tóth1, J B van de Meer, M F Jonkman

  • 1Center for Bullous Skin Diseases, Department of Dermatology, Groningen University Hospital, The Netherlands. g.g.toth@derm.azg.nl

Journal of the European Academy of Dermatology and Venereology : JEADV
|December 17, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed?

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

Keratinocyte footprint assay discriminates antilaminin-332 pemphigoid from all other forms of pemphigoid diseases.

The British journal of dermatology·2019
Same author

Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases.

The British journal of dermatology·2018
Same author

A rare case with prominent features of both discoid lupus erythematosus and pemphigus foliaceus.

Journal of the European Academy of Dermatology and Venereology : JEADV·2018
Same author

Cardiomyopathy in patients with epidermolysis bullosa simplex with mutations in KLHL24.

The British journal of dermatology·2018

High-dose glucocorticoid pulse therapy for severe pemphigus shows promise, with minor side effects and potential for oral administration. Further research is needed to confirm its long-term efficacy and steroid-sparing effects.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • High-dose glucocorticoid pulse therapy is a treatment for autoimmune diseases and transplant rejection.
  • Severe pemphigus is a primary dermatological indication for this therapy.

Purpose of the Study:

  • To review the sequelae of pulse therapy in patients with pemphigus.
  • To assess the efficacy and adverse events of glucocorticoid pulse therapy.
  • To explore the feasibility of oral dexamethasone pulse administration for future clinical trials.

Main Methods:

  • Retrospective review of 14 patients with pemphigus treated with pulse therapy.
  • Analysis of treatment outcomes, including remission rates and disease flare-ups.
  • Documentation of adverse events associated with pulse therapy.

Related Experiment Videos

Main Results:

  • Seven out of 14 patients achieved complete remission; three required additional pulse courses.
  • Adverse events were minor and occurred in 60% of patients, including flushing, sleep disturbances, and mood changes.
  • Oral administration of dexamethasone pulse therapy was found to be feasible, enabling double-blind placebo-controlled trials.

Conclusions:

  • Glucocorticoid pulse therapy can induce remission in severe pemphigus with generally minor adverse events.
  • The potential for oral dexamethasone pulse administration offers a pathway for more rigorous clinical trials.
  • This retrospective study could not establish a steroid-sparing effect.